List view / Grid view




TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease

13 February 2015 | By

Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix's eASC product, Cx601.